Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

In 2023, the U.S. Food and Drug Administration approved the first medication to treat people with Friedreich’s ataxia who are age 16 or older. Given that Friedreich’s ataxia is a genetic ...

Biohaven said its experimental treatment for a rare neurological condition showed "a robust and clinically meaningful" ...

In order to improve the quality of life of patients with the Ataxia disease, the biotechnological and pharmaceutical industry ...

Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the ...

Biohaven Ltd. shares rose sharply after its experimental drug slowed the progress of a rare nerve disease in a study, which ...

has granted Orphan Drug Designation to Papillon’s PPL-001, an experimental treatment for Friedreich's ataxia. “We are pleased that the FDA has granted Orphan Drug Designation to our program ...

Larimar Therapeutics (NASDAQ:LRMR) was started at outperform by Wedbush based on the company’s drug candidate nonlabofusp for ...

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for ...

Bill Nye, who has helped make science a part of pop culture for a generation of adults and children, is now using his ...